Liquid biopsy technology for cancer detection has significantly advanced with the integration of exosomes, which allow for the analysis of genetic material from viable tumor cells rather than relying solely on dead cell byproducts. This represents a leap forward in diagnostic capabilities, offering increased sensitivity and enabling earlier identification of subclones, as evidenced in metastatic breast cancer. The stability of RNA within exosomes simplifies processing, making implementation feasible in standard laboratories and pushing towards more sophisticated biomarker discovery for various cancers.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.